PACEPro - Mood Management Pilot

University of California San Diego

Status: Completed

Conditions: Depression

Treatments: Behavioral: Personalized support from a Family Nurse Practitioner; Behavioral: Physical Activity; Behavioral: Mood Management Skills; Drug: Lexapro, an antidepressant medicine

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00416221

LXP-MD-106

2005-3889(UCSD Number)

Details and patient eligibility

About

Researchers at the University of California at San Diego (UCSD) are conducting a 12-week study to test the PACEPRO program. This program is designed to reduce depression by providing:

Lexapro, an antidepressant medicine...Learn More Physical activity information and pedometer Mood management skills and a Mood Mastery Guide Personalized support from a Family Nurse Practitioner

Enrollment: 40 patients

Sex: All

Ages: 25 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Have been diagnosed with mild to moderate depression
• Are willing to take the antidepressant Lexapro
• Can access and use Email and the Internet
• Are willing and able to be physically active
• Access to a primary care physician

Exclusion criteria

Subjects will be excluded from participation for the following reasons:

• Pregnancy or breastfeeding
• Narrow angle glaucoma
• Any uncontrolled medical condition or any medical condition which would represent a contraindication to Escitalopram Oxalate Lexapro® pharmacotherapy. Any concomitant non-psychotropic medications that the physician determines are a contraindication to Escitalopram Oxalate Lexapro® pharmacotherapy Bipolar disorder, or any psychotic or organic mental disorder or dementia
• History of intolerance or allergy to Lexapro, or of prior failed treatment for depression with Lexapro
• Current substance abuse or dependency
• Current active suicidal ideation
• Current use of herbal psychoactive treatments such as St. John's Wort
• Concurrent psychotropic medication is not permitted for 2 weeks prior to randomization (4 weeks in the case of fluoxetine) or at any point after
• Receipt of formal psychotherapy concurrently
• Inability, in the investigator's opinion, to comply with study procedures or assessments
• Inability to exercise

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)